2022 BO42452 – A Phase Ib, Randomized, Placebo-Controlled Study Evaluating The Safety, Pharmacokinetics, Pharmacodynamics, And Efficacy Of Crovalimab For The Management Of Acute Uncomplicated Vaso Occlusive Episodes (VOE) In Patients With Sickle Cell Disease (SCD) Case StudiesOngoing 2022 BO42452 – A Phase Ib, Randomized, Placebo-Controlled Study Evaluating The Safety, Pharmacokinetics, Pharmacodynamics, And Efficacy Of Crovalimab For The Management Of Acute Uncomplicated Vaso Occlusive Episodes (VOE) In Patients With Sickle Cell Disease (SCD)
2022 BO42451 – A Randomized Double-Blind Phase IIa Study Evaluating The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Crovalimab As Adjunct Treatment In Prevention Of Vaso-Occlusive Episodes (Voe) In Sickle Cell Disease (SCD) Case StudiesOngoing 2022 BO42451 – A Randomized Double-Blind Phase IIa Study Evaluating The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Crovalimab As Adjunct Treatment In Prevention Of Vaso-Occlusive Episodes (Voe) In Sickle Cell Disease (SCD)
2018 GBT 034 – An Open-label Extension Study of Voxelotor (GBT 440) Administered Orally to Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials (GBT440-034) Case StudiesOngoing 2018 GBT 034 – An Open-label Extension Study of Voxelotor (GBT 440) Administered Orally to Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials (GBT440-034)
2021 GBT440-032 “HOPE Kids 2” – A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of Voxelotor (GBT440) in Paediatric Participants with Sickle Cell Disease and an Open-label Study in Infants with Sickle Cell Disease Case StudiesOngoing 2021 GBT440-032 “HOPE Kids 2” – A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of Voxelotor (GBT440) in Paediatric Participants with Sickle Cell Disease and an Open-label Study in Infants with Sickle Cell Disease
2022 GBT440-042 – Phase 3, Multicenter, Randomized, Double-Blind, PlaceboControlled Trial to Evaluate the Efficacy of Voxelotor for the Treatment of Leg Ulcers in Patients with Sickle Cell Disease Case StudiesOngoing 2022 GBT440-042 – Phase 3, Multicenter, Randomized, Double-Blind, PlaceboControlled Trial to Evaluate the Efficacy of Voxelotor for the Treatment of Leg Ulcers in Patients with Sickle Cell Disease
2021 GBT2104-131 – A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vasoocclusive Crises Case StudiesOngoing 2021 GBT2104-131 – A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vasoocclusive Crises
2022 GBT2104-133 – An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial Case StudiesOngoing 2022 GBT2104-133 – An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial
2021 AG348-C-020 ‘Agios’ – Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease Case StudiesOngoing 2021 AG348-C-020 ‘Agios’ – Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease
2021 FORMA-4202-HEM-301 – An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease Case StudiesOngoing 2021 FORMA-4202-HEM-301 – An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease
